




Theravance Biopharma Inc
Rank 116 of 332



The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Theravance Biopharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 312%, being 60% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	378,749
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	62,552
Liabilities, Non-Current	0
Other Assets	52,494
Other Compr. Net Income	-480
Other Expenses	36,271
Other Liabilities	0
Other Net Income	4,959
Other Revenues	15,386
Property and Equipment	10,157
Research and Development	173,887
Selling, General and Administrative Expense	95,592

Output Variable	Value in 1000 USD
Assets	441,400
Liabilities	62,552
Expenses	305,750
Revenues	15,386
Stockholders Equity	378,848
Net Income	-285,405
Comprehensive Net Income	-285,645
BaseVar	415,264
ECR before Limited Liability	214%
Economic Capital Ratio	312%